CMS sets up negotiating framework for expensive sickle cell disease gene therapies
CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.
CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.
What's Your Reaction?
